SCHEMBL1498152

SCHEMBL1498152

[NH]C(=O)CCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6706926 0.84
Succinic Acid SCHEMBL29808469 0.80
Succinic Acid SCHEMBL21867134 0.80 LMNA (1.00)
Succinic Acid SCHEMBL4269130 0.80 LMNA (1.00)
Succinic Acid SCHEMBL24696 0.80 LMNA (1.00)
Succinic Acid SCHEMBL829 0.80
Succinic Acid SCHEMBL1331200 0.80
Succinic Acid SCHEMBL3799615 0.80
Succinic Acid SCHEMBL4269135 0.80 LMNA (1.00)
Succinic Acid SCHEMBL8992010 0.80 LMNA (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US claimed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP claimed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US claimed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP claimed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US claimed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO claimed
US-5210290-A NMR diagnostic aid SCHERING AKTIENGESELLSCHAFT (DE) 1993-05-11 US claimed
EP-0266735-B1 FIBER REACTIVE YELLOW MONOAZO COMPOUND HAVING TWO VINYLSULFONE TYPE GROUPS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-02-06 EP claimed
EP-0207474-B1 SILVER HALIDE PHOTOGRAPHIC MATERIAL KONICA CORPORATION (JP) 1990-08-29 EP claimed
US-4910298-A Containing triamine substituted triazole ring SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-03-20 US claimed
EP-0266735-A1 Fiber reactive yellow monoazo compound having two vinylsulfone type groups SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-05-11 EP claimed
EP-0207474-A2 Silver halide photographic material KONICA CORPORATION (JP) 1987-01-07 EP claimed
US-10358567-B2 Compound, ink, ink cartridge and ink jet recording method CANON KABUSHIKI KAISHA (JP) 2019-07-23 US disclosed
US-10190009-B2 Ink composition, ink jet recording method using same, and colored material NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20170247557-A1 COMPOUND, INK, INK CARTRIDGE AND INK JET RECORDING METHOD CANON KABUSHIKI KAISHA (JP) 2017-08-31 US disclosed
US-9587129-B2 Ink composition and ink set SEIKO EPSON CORPORATION (JP) 2017-03-07 US disclosed
EP-0000500-A2 Cephalosprin derivatives, process for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1979-02-07 EP disclosed
US-4113867-A ANTHELMINTICS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1978-09-12 US disclosed
US-4041161-A ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1977-08-09 US disclosed
US-4001411-A ANTHELMINTICS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1977-01-04 US disclosed